Four QUARTET-affiliated trials are currently recruiting patients and participating in the site approval and individual case review procedures: FaR-RMS (EpSSG), HRMB (SIOPE Brain Tumour Group), LINES (SIOPEN), and HR-NBL2 (SIOPEN). Good progress has been made for ATRT01 (SIOPE Brain Tumour Group) and INTER-EWING-1 (Euro-Ewing Consortium); we hope to open and commence site approval and case review procedures in the coming months. We are pleased to report that a total of 182 site RTQA approvals have been completed for 135 institutions across 21 countries; a further 65 are in progress with many more planned. Individual case (plan) reviews have been performed for 498 patients; we are seeing an average plan rejection rate of 48% but thanks to prospective plan review corrections have been possible for 83% of cases. This highlights the value of QUARTET to continue providing prospective case review for children and adolescents with cancer.
We’re very pleased to announce that Maria Chiara Lo Greco has joined the QUARTET team as a research fellow. Maria Chiara is an Italian Radiation Oncology resident, keenly interested in paediatric brain tumours and soft-tissue sarcomas. Hence, she will be involved in some QUARTET-affiliated trials and research projects, relating to FaR-RMS, HRMB, and ATRT01.
The QUARTET consortium will hold its annual meeting on 16 November in Brussels to discuss the current status of the project and plans for the future.
As always, further information can be found on the QUARTET website which now has an added resource section, where you can find all research outputs such as abstracts and the recently published activity report. The findings from the 2016-2022 Activity Report were also presented at SIOP 2023.